Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Short-Term Effects of Medicinal Cannabis Therapy on Spasticity in Multiple Sclerosis

This study has been completed.
Sponsor:
Information provided by:
Center for Medicinal Cannabis Research
ClinicalTrials.gov Identifier:
NCT00248378
First received: November 2, 2005
Last updated: June 21, 2006
Last verified: June 2006

November 2, 2005
June 21, 2006
September 2001
Not Provided
Reduction in spasticity as indicated by the: Ashworth Spasticity Scale, Timed 25-ft Walk, and Grooved Pegboard Test
Same as current
Complete list of historical versions of study NCT00248378 on ClinicalTrials.gov Archive Site
  • Tolerability of study drug as determined by the Brief Symptom Inventory, Subjective Ratings of High and Sedation-Revised, and UKU Side Effect Rating Scale
  • Effect of study drug on global functioning and quality of life as indicated by the Multiple Sclerosis Quality of Life Inventory
Same as current
Not Provided
Not Provided
 
Short-Term Effects of Medicinal Cannabis Therapy on Spasticity in Multiple Sclerosis
Short-Term Effects of Medicinal Cannabis Therapy on Spasticity in Multiple Sclerosis

The purpose of this study is to determine whether or not smoked marijuana improves spasticity in patients with multiple sclerosis.

Studies of cannabinoids for spasticity in MS have had mixed results but clinical studies have been small, generally not properly controlled, with results controversial, and difficult to interpret. Recently, investigators in the UK and US tested the ability of cannabinoids to control spasticity and tremor symptoms of the MS-like disease, experimental allergic encephalomyelitis, in mice (Baker et al, 2000). The authors found that four different cannabinoids quantitatively ameliorated both tremor and spasticity in diseased mice; thus providing rationale for patients' reports of the therapeutic effects of cannabis in the control of their MS symptoms.

The present study will be a randomized, placebo-controlled, crossover design of 30 patients who will be assessed before and after treatment for 3 consecutive days (Phase I), undergo washout-out for a total of 11 days, and then cross over to either the placebo or active treatment phase (Phase II), depending on what they received during Phase I. At each study visit, patients will utilize a controlled puff procedure to help ensure stable intake (Levin et al, 1989).

Comparisons: A single dose of 4% THC marijuana cigarette each day for 3 days will be compared to a placebo administered under the same dosing conditions for the relief of spasticity, drug tolerability, and changes in global functioning and quality of life indices.

Interventional
Phase 1
Phase 2
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Crossover Assignment
Masking: Double-Blind
Primary Purpose: Treatment
Multiple Sclerosis
Drug: Smoked Cannabis
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
30
March 2005
Not Provided

Inclusion Criteria:

  • Clinically definite or probable, laboratory-supported MS
  • Complaints of spasticity and at least moderate increase in tone as evidenced by a score of >= 2 on the Modified Ashworth Scale at either the elbow, hip, or knee
  • If on disease-modifying therapy ("ABC"), have been on a stable dose for at least six months
  • Fluent in English
  • If not cannabis-naive, must refrain from smoking cannabis for two weeks prior to screening (confirmed by urinalysis)
  • If on either lioresal (Baclofen) or tizanadine (Zanaflex), have been on a stable dose for at least three months
  • >=18 years of age

Exclusion Criteria:

  • Axis I psychiatric disorder especially depression or significant neurological disease other than MS as determined by the PI
  • Recent history of active substance abuse defined as daily use for at least 14 days within the past month
  • Drug use restrictions, eg, subjects on probation or parole, employment involving high risk to themselves and/or the public (airline pilot, bus driver, etc.)
  • Any unstable medical health problem
  • Any known pulmonary disorders, including tuberculosis, asthma, or COPD
  • Pregnant or nursing
  • Require benzodiazepines to control spasticity
  • Require high doses of analgesic medications on a daily basis
Both
18 Years and older
No
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT00248378
C00-SD-103, 030002
Not Provided
Not Provided
Center for Medicinal Cannabis Research
Not Provided
Principal Investigator: Jody Corey-Bloom, M.D., Ph.D. University of California, San Diego
Center for Medicinal Cannabis Research
June 2006

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP